 Lipocine Inc. Nasdaq: LPCN, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data for lead candidate TLANDOTM will be presented at the American Urological Association AUA Virtual Experience, to take place May 15-17, 2020. TLANDO is an oral testosterone replacement therapy TRT product candidate being developed for adult males with conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism. 